Alpha Tau Medical Ltd.
- Open
- 14.38
- Day high
- 14.40
- Day low
- 13.45
- Prev close
- 14.27
- Volume
- 484K
- Mkt cap
- $1.2B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 17.6
- P/S
- —
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$1.3M over the last 3 months (0 open-market buys, 10 sales)
- 🏛Institutions mixed (13F)
Alpha Tau Medical Ltd. (DRTS) is a Healthcare company listed on NASDAQ. The stock is up 299% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 10 sales (SEC Form 4).
Alpha Tau Medical Ltd. (DRTS) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 3 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
DRTS earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 10, 2026 | $-0.14 | $-0.50 | -254.9% | $100000 | -30.8% |
| May 18, 2026 | $-0.13 | $-0.26 | -100.0% | — | — |
| Mar 9, 2026 | $-0.12 | $-0.14 | -15.7% | — | — |
| Nov 20, 2025 | $-0.12 | $-0.14 | -16.7% | — | — |
| May 19, 2025 | $-0.14 | $-0.12 | +14.3% | — | — |
| Mar 12, 2025 | $-0.13 | $-0.13 | +0.0% | — | — |
| Aug 14, 2024 | $-0.13 | $-0.11 | +15.4% | — | — |
| May 20, 2024 | $-0.13 | $-0.11 | +15.4% | — | — |
| Mar 7, 2024 | $-0.13 | $-0.11 | +15.4% | — | — |
| Nov 16, 2023 | $-0.12 | $-0.07 | +41.7% | — | — |
| Aug 28, 2023 | $-0.13 | $-0.12 | +7.7% | — | — |
| May 23, 2023 | $-0.09 | $-0.12 | -33.3% | — | — |
DRTS insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 7, 2026 | Levy Raphiofficer: Chief Financial Officer | Sell | 2,270 | $14.00 |
| Jul 7, 2026 | Levy Raphiofficer: Chief Financial Officer | Option | 2,270 | $2.98 |
| Jul 6, 2026 | Levy Raphiofficer: Chief Financial Officer | Sell | 17,873 | $13.00 |
| Jul 6, 2026 | Levy Raphiofficer: Chief Financial Officer | Option | 17,873 | $2.98 |
| Jul 2, 2026 | Levy Raphiofficer: Chief Financial Officer | Option | 2,127 | $2.98 |
| Jul 2, 2026 | Levy Raphiofficer: Chief Financial Officer | Sell | 2,127 | $13.02 |
| Jul 1, 2026 | Levy Raphiofficer: Chief Financial Officer | Sell | 20,000 | $12.00 |
| Jun 26, 2026 | Levy Raphiofficer: Chief Financial Officer | Sell | 15,778 | $11.00 |
| Jun 26, 2026 | Levy Raphiofficer: Chief Financial Officer | Sell | 4,222 | $11.00 |
| Jun 25, 2026 | Levy Raphiofficer: Chief Financial Officer | Sell | 2,500 | $10.00 |
| Jun 25, 2026 | Levy Raphiofficer: Chief Financial Officer | Sell | 15,000 | $9.47 |
| Jun 4, 2026 | Levy Raphiofficer: Chief Financial Officer | Sell | 17,500 | $10.90 |
| Jun 4, 2026 | Levy Raphiofficer: Chief Financial Officer | Sell | 15,000 | $10.76 |
Source: DRTS SEC Form 4 filings, latest Jul 7, 2026. For informational purposes only — not investment advice.
See the full DRTS insider & 13F page →Alpha Tau Medical Ltd. company profile
Overview
Alpha Tau Medical Ltd. (NASDAQ:DRTS) is a clinical-stage oncology therapeutics company founded in 2015 and headquartered in Jerusalem, Israel. The company went public in March 2021 and focuses on developing innovative radiation therapy technology for treating solid tumors. Alpha Tau's core innovation centers around a proprietary technology called Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), which represents a novel approach to cancer treatment using radioactive alpha particles delivered directly to tumor sites.
Business
Alpha Tau Medical operates in the oncology therapeutics sector, specifically developing advanced radiation therapy technologies for cancer treatment. The company's primary focus is its Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) platform, which represents a fundamentally different approach to radiation oncology compared to traditional external beam radiation or brachytherapy. Alpha DaRT technology works by inserting tiny radioactive sources directly into tumors, where they release alpha particles - a type of radiation with very short range but high energy density. Unlike conventional radiation therapy that delivers energy from outside the body or through larger radioactive implants, Alpha DaRT uses seeds that diffuse alpha-emitting atoms throughout the tumor tissue. This approach aims to deliver highly targeted radiation that destroys cancer cells while minimizing damage to surrounding healthy tissue. The technology is currently being evaluated in clinical trials for multiple cancer types including skin cancer, oral cancer, pancreatic cancer, and breast cancer. Additionally, the company is conducting preclinical research for hepatocellular carcinoma (liver cancer), glioblastoma multiforme (an aggressive brain cancer), lung cancer, and other solid tumor types. As a clinical-stage company, Alpha Tau has not yet generated commercial revenue and remains focused entirely on research and development activities.
Revenue model
As a clinical-stage biotechnology company, Alpha Tau Medical does not currently generate revenue from product sales. The company operates on a research and development model funded primarily through equity financing, with the goal of eventually commercializing its Alpha DaRT technology once regulatory approvals are obtained. The company's future business model will likely center on medical device sales and licensing once Alpha DaRT receives regulatory clearance. Potential revenue streams include direct sales of Alpha DaRT systems and radioactive seeds to hospitals and cancer treatment centers, licensing agreements with medical device distributors or larger healthcare companies, and potentially royalty arrangements in various geographic markets. Key factors that could impact the company's future profitability include the success of ongoing clinical trials, regulatory approval timelines from agencies like the FDA and European Medicines Agency, competitive positioning against established radiation therapy technologies, healthcare reimbursement policies for the treatment, and the company's ability to scale manufacturing and distribution. The oncology market is highly competitive with established players offering various radiation therapy solutions, which could pressure pricing and market penetration. Additionally, the specialized nature of alpha particle therapy may require significant physician education and training, potentially slowing adoption rates. Healthcare cost containment pressures could also impact reimbursement levels and hospital purchasing decisions for new cancer technologies.
Competitive moat
Alpha Tau Medical's competitive position is built primarily around its proprietary Alpha DaRT technology platform, which represents a differentiated approach in the radiation oncology field. The company's potential moat stems from its intellectual property portfolio covering the alpha particle diffusion methodology, specialized manufacturing processes for the radioactive seeds, and clinical expertise in alpha-emitter applications for solid tumors. However, the strength of this moat remains largely unproven given the company's clinical-stage status. The radiation oncology market includes well-established competitors with significant resources, including companies like Varian Medical Systems (now part of Siemens), Elekta, and various brachytherapy device manufacturers. These competitors have extensive distribution networks, regulatory expertise, and established relationships with oncology centers that could pose significant barriers to Alpha Tau's market entry. The company faces potential disruption from multiple directions, including advances in external beam radiation technologies like proton therapy and stereotactic radiosurgery, immunotherapy combinations that may reduce reliance on radiation, and other emerging targeted cancer therapies. Additionally, larger medical device companies could potentially develop competing alpha-emitter technologies or acquire smaller competitors in this space. The relatively narrow focus on alpha particle therapy, while potentially providing differentiation, also creates concentration risk if the technology fails to demonstrate superior clinical outcomes or faces regulatory challenges.
Risks & safety
Alpha Tau Medical presents a mixed margin of safety profile typical of clinical-stage biotechnology companies, with strong balance sheet liquidity but significant execution risks. • Liquidity and Solvency: Strong current ratio of 7.4x as of FY 2024, with $13.7 million in cash and short-term investments against minimal debt obligations. However, the company burned approximately $22 million in free cash flow during 2024. • Cash Runway: Based on current burn rates of roughly $20-22 million annually, the company has less than one year of operating runway with existing cash, indicating near-term financing needs. • Valuation Metrics: Trading at negative earnings multiples due to development-stage losses. Price-to-book ratio of 3.5x suggests some premium to tangible assets, though much of the asset base consists of development-related intangibles. • Debt Position: Minimal debt with debt-to-equity ratio of 0.20, providing financial flexibility for future fundraising. • Other Considerations: No revenue generation creates binary risk profile dependent entirely on clinical trial outcomes and regulatory approvals. Graham net-net working capital provides some downside protection at approximately 52% of market value.
Recent development
Based on the available financial data, Alpha Tau Medical has maintained consistent focus on advancing its Alpha DaRT technology through clinical development over recent years. The company has sustained its research and development activities with annual operating losses in the $28-32 million range, indicating ongoing investment in clinical trials and regulatory preparation. The company's cash position has fluctuated significantly, declining from over $15 million at the end of 2023 to under $6 million by Q2 2024, before recovering to nearly $14 million by year-end 2024, suggesting additional financing activities during the year. This pattern reflects the typical funding cycles of clinical-stage biotechnology companies that periodically raise capital to fund operations. Alpha Tau has expanded its clinical program across multiple cancer types, with active trials in skin, oral, pancreatic, and breast cancers, while advancing preclinical research in liver cancer, brain tumors, and lung cancer. This diversified approach across multiple tumor types represents a strategic effort to maximize the commercial potential of the Alpha DaRT platform, though it also increases development costs and complexity. The company appears to be building toward potential regulatory submissions, though specific timelines for pivotal trials or commercialization milestones are not detailed in the available financial information.
DRTS company profile · for informational purposes only — not investment advice.
Track DRTS with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free